NASDAQ$RMTI
Rockwell Medical Inc · Q3 2020 earnings
Q3 2020 earnings · · Investor relations
Briefing
Reported financial results and business update for the three months ended September 30, 2020.
Rockwell Medical reported Q3 2020 revenue of $15.3 million and ended the quarter with $67.3 million in cash, cash equivalents and investments. The company is preparing for the U.S. commercial launch of Triferic® AVNU expected in Q1 2021 and anticipates enrolling the first patient in a Phase 3 clinical trial of Triferic in China.
- Net sales for the concentrates business were $15.0 million.
- Net sales for Triferic were $0.3 million.
- Approximately 3,400 contracted patients on therapy, representing approximately 500,000 annualized treatments.
- Cash, cash equivalents, and investments totaled $67.3 million as of September 30, 2020.
Headline financials
Revenue & EPS history
Rockwell Medical · Revenue · Quarterly
$15.3M
Forward guidance
Rockwell Medical intends to use the net proceeds to advance the development of FPC, currently indicated for the maintenance of hemoglobin in dialysis, in new indications, including for the treatment of anemia in the home infusion setting, as well as for working capital and general corporate purposes.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports · overlaid with Q3 2020
-3.1%
Avg return
Earnings day
-3.3%
Avg return
5 days after
-3.0%
Avg return
30 days after
38%
24 / 63 earnings
Positive
+28.2%
Q3 2022
Best reaction
-43.4%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | -13.0% | -11.3% | — | |
| Q1 2026 | -3.6% | +2.8% | -18.2% | |
| Q3 2025 | -9.2% | -17.1% | -12.4% | |
| Q1 2025 | -6.4% | -9.8% | -11.6% | |
| Q4 2024 | -20.5% | -31.8% | -41.5% | |
| Q3 2024 | -43.4% | -49.2% | -55.5% | |
| Q2 2024 | +22.6% | +35.6% | +68.4% | |
| Q1 2024 | +0.6% | +4.1% | +8.2% | |
| Q4 2023 | +3.6% | +0.0% | -12.1% | |
| Q3 2023 | +12.2% | +5.1% | -11.2% | |
| Q2 2023 | -7.4% | -25.8% | -28.5% | |
| Q1 2023 | -4.5% | -3.7% | +71.8% | |
| Q4 2022 | +14.6% | +18.4% | +74.7% | |
| Q3 2022 | +28.2% | +19.4% | +0.0% | |
| Q2 2022 | +12.0% | +7.1% | -14.1% | |
| Q1 2022 | +3.0% | -17.3% | -34.7% | |
| Q4 2021 | -13.6% | -11.4% | -27.3% | |
| Q3 2021 | -7.7% | -7.7% | -21.2% | |
| Q2 2021 | -6.2% | -10.8% | -4.6% | |
| Q1 2021 | -2.2% | -4.3% | +0.0% | |
| Q4 2020 | +4.5% | -1.8% | -13.5% | |
| Q3 2020 | +1.1% | +5.6% | +33.7% | |
| Q2 2020 | +4.2% | +0.0% | -26.3% | |
| Q1 2020 | -4.7% | -12.9% | -9.0% | |
| Q4 2019 | -42.7% | -25.0% | -22.6% | |
| Q3 2019 | +5.4% | +12.4% | +23.7% | |
| Q2 2019 | -5.6% | +2.0% | +9.3% | |
| Q1 2019 | -7.5% | -11.9% | -25.6% | |
| Q4 2018 | +3.0% | +23.9% | +4.7% | |
| Q3 2018 | +8.9% | +12.3% | -16.2% | |
| Q2 2018 | -15.5% | -12.4% | -13.6% | |
| Q1 2018 | -2.5% | +5.8% | -8.8% | |
| Q4 2017 | -17.5% | -18.3% | -14.1% | |
| Q3 2017 | +9.6% | +11.6% | +3.4% | |
| Q2 2017 | -4.2% | -1.5% | -5.4% | |
| Q1 2017 | -1.2% | -9.1% | +9.3% | |
| Q4 2016 | +10.0% | +10.2% | +10.6% | |
| Q3 2016 | -20.5% | -3.5% | +27.3% | |
| Q2 2016 | -8.9% | -8.1% | -10.2% | |
| Q1 2016 | +19.7% | — | — | |
| Q4 2015 | -36.8% | — | — | |
| Q3 2015 | -10.5% | — | — | |
| Q2 2015 | +11.5% | — | — | |
| Q1 2015 | +12.9% | — | — | |
| Q4 2014 | -6.6% | — | — | |
| Q3 2014 | +5.7% | — | — | |
| Q2 2014 | +0.1% | — | — | |
| Q1 2014 | -8.5% | — | — | |
| Q3 2013 | -0.8% | — | — | |
| Q2 2013 | +0.6% | — | — | |
| Q1 2013 | -7.6% | — | — | |
| Q4 2012 | -19.9% | — | — | |
| Q3 2012 | -3.3% | — | — | |
| Q2 2012 | -6.4% | — | — | |
| Q1 2011 | -0.2% | — | — | |
| Q1 2012 | +1.0% | — | — | |
| Q4 2011 | -4.4% | — | — | |
| Q3 2011 | -9.3% | — | — | |
| Q3 2010 | -9.3% | — | — | |
| Q2 2011 | -0.1% | — | — | |
| Q2 2010 | -0.1% | — | — | |
| Q4 2010 | -1.4% | — | — | |
| Q1 2010 | +3.4% | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro